CSTL vs. FLGT, CDNA, CELC, VRDN, SERA, BDSX, PSNL, RNLX, XGN, and DMTK
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Fulgent Genetics (FLGT), CareDx (CDNA), Celcuity (CELC), Viridian Therapeutics (VRDN), Sera Prognostics (SERA), Biodesix (BDSX), Personalis (PSNL), Renalytix (RNLX), Exagen (XGN), and DermTech (DMTK). These companies are all part of the "medical laboratories" industry.
Castle Biosciences (NASDAQ:CSTL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Castle Biosciences has a net margin of -12.28% compared to Fulgent Genetics' net margin of -57.72%. Fulgent Genetics' return on equity of -2.92% beat Castle Biosciences' return on equity.
In the previous week, Castle Biosciences had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 2 mentions for Castle Biosciences and 0 mentions for Fulgent Genetics. Castle Biosciences' average media sentiment score of 0.42 beat Fulgent Genetics' score of -0.08 indicating that Castle Biosciences is being referred to more favorably in the media.
Castle Biosciences has higher earnings, but lower revenue than Fulgent Genetics. Castle Biosciences is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by company insiders. Comparatively, 32.7% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Castle Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Castle Biosciences presently has a consensus target price of $31.57, indicating a potential upside of 26.69%. Fulgent Genetics has a consensus target price of $30.00, indicating a potential upside of 40.06%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Castle Biosciences.
Fulgent Genetics received 163 more outperform votes than Castle Biosciences when rated by MarketBeat users. However, 62.31% of users gave Castle Biosciences an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
Summary
Castle Biosciences beats Fulgent Genetics on 10 of the 18 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
